Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$1.69	$1.73	$1.43 ▼ $5.97	$23.61M	1.26	45,780 shs	14,006 shs
GALT Galectin Therapeutics	$3.29 +37.7%	$1.43	$0.73 ▼ $3.30	$208.23M	0.54	388,765 shs	5.37 million shs
IVVD Invivyd	$0.75 +3.1%	$0.73	$0.35 ▼ $2.74	$89.85M	0.63	4.54 million shs	522,900 shs
MGNX MacroGenics	$1.37	$1.51	$0.99 ▼ $5.77	$86.43M	1.65	853,572 shs	788,875 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	0.00%	-6.63%	-9.14%	-19.52%	-66.47%
GALT Galectin Therapeutics	+37.66%	+149.24%	+147.37%	+115.03%	+41.20%
IVVD Invivyd	+3.05%	-13.81%	-3.43%	+1.41%	-46.50%
MGNX MacroGenics	0.00%	-19.88%	-13.84%	-34.76%	-66.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALC CalciMedica	3.2059 of 5 stars	3.5	5.0	0.0	1.9	3.3	0.0
GALT Galectin Therapeutics	1.3691 of 5 stars	3.5	0.0	0.0	2.0	1.7	0.0
IVVD Invivyd	2.8599 of 5 stars	3.6	4.0	0.0	0.0	3.3	0.6
MGNX MacroGenics	3.6776 of 5 stars	3.2	1.0	4.4	1.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALC CalciMedica	3.00	Buy	$18.00	965.09% Upside
GALT Galectin Therapeutics	3.00	Buy	$6.00	82.37% Upside
IVVD Invivyd	3.25	Buy	$5.85	681.04% Upside
MGNX MacroGenics	2.40	Hold	$5.71	317.10% Upside

Current Analyst Ratings Breakdown

Latest CALC, MGNX, IVVD, and GALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/28/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $5.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
5/16/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
5/15/2025	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/14/2025	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.00
4/2/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
4/1/2025	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
3/26/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/25/2025	MGNX MacroGenics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $2.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALC CalciMedica	N/A	N/A	N/A	N/A	$1.07 per share	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.68) per share	N/A
IVVD Invivyd	$25.38M	3.54	N/A	N/A	$0.56 per share	1.34
MGNX MacroGenics	$149.96M	0.58	N/A	N/A	$1.85 per share	0.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALC CalciMedica	-$13.70M	-$1.56	N/A	N/A	N/A	N/A	-171.81%	-100.43%	8/11/2025 (Estimated)
GALT Galectin Therapeutics	-$47.05M	-$0.72	N/A	N/A	N/A	N/A	N/A	-216.05%	8/11/2025 (Estimated)
IVVD Invivyd	-$169.93M	-$1.20	N/A	6.81	N/A	-389.01%	-165.24%	-99.71%	8/13/2025 (Estimated)
MGNX MacroGenics	-$66.97M	-$0.89	N/A	N/A	N/A	-36.23%	-59.84%	-23.45%	8/5/2025 (Estimated)

Latest CALC, MGNX, IVVD, and GALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	GALT Galectin Therapeutics	-$0.20	-$0.15	+$0.05	-$0.15	N/A	N/A
5/15/2025	Q1 2025	IVVD Invivyd	-$0.04	-$0.14	-$0.10	-$0.14	$34.45 million	$11.30 million
5/14/2025	Q1 2025	CALC CalciMedica	-$0.43	-$0.36	+$0.07	-$0.36	N/A	N/A
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million
3/31/2025	Q4 2024	GALT Galectin Therapeutics	-$0.16	-$0.19	-$0.03	-$0.19	N/A	N/A
3/27/2025	Q4 2024	CALC CalciMedica	-$0.48	-$0.34	+$0.14	-$0.34	N/A	N/A
3/20/2025	Q4 2024	IVVD Invivyd	-$0.25	-$0.15	+$0.10	-$0.15	$13.57 million	$13.80 million
3/20/2025	Q4 2024	MGNX MacroGenics	-$0.23	-$0.25	-$0.02	-$0.25	$34.17 million	$49.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALC CalciMedica	0.79	5.66	5.66
GALT Galectin Therapeutics	N/A	0.08	0.08
IVVD Invivyd	N/A	1.53	1.53
MGNX MacroGenics	N/A	3.28	3.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALC CalciMedica	N/A
GALT Galectin Therapeutics	11.68%
IVVD Invivyd	70.36%
MGNX MacroGenics	96.89%

Insider Ownership

Company	Insider Ownership
CALC CalciMedica	41.55%
GALT Galectin Therapeutics	50.10%
IVVD Invivyd	25.40%
MGNX MacroGenics	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALC CalciMedica	30	13.97 million	8.17 million	No Data
GALT Galectin Therapeutics	9	63.29 million	31.58 million	Optionable
IVVD Invivyd	100	119.96 million	89.49 million	Optionable
MGNX MacroGenics	430	63.09 million	54.89 million	Optionable

CALC, MGNX, IVVD, and GALT Headlines

Recent News About These Companies

MacroGenics (NASDAQ:MGNX) Shares Pass Below Two Hundred Day Moving Average - Time to Sell?

June 18 at 3:29 AM | marketbeat.com

MacroGenics’ SWOT analysis: biotech firm’s stock faces pivotal year ahead

June 16 at 8:00 PM | investing.com

MacroGenics lands $70M 'infusion of cash' to advance clinical programs

June 13, 2025 | bizjournals.com

MacroGenics: Working On That Road To Recovery

June 11, 2025 | seekingalpha.com

MacroGenics Shares Rise on Royalty-Purchase Agreement

June 10, 2025 | marketwatch.com

MacroGenics Target of Unusually Large Options Trading (NASDAQ:MGNX)

June 10, 2025 | marketbeat.com

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement

June 10, 2025 | globenewswire.com

MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts

June 9, 2025 | americanbankingnews.com

MacroGenics (NASDAQ:MGNX) Upgraded by Wall Street Zen to "Hold" Rating

June 7, 2025 | marketbeat.com

MacroGenics, Inc. (NASDAQ:MGNX) Given Average Recommendation of "Hold" by Analysts

June 4, 2025 | marketbeat.com

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

June 3, 2025 | globenewswire.com

MacroGenics (NASDAQ:MGNX) Upgraded to Hold at Wall Street Zen

May 31, 2025 | marketbeat.com

Millennium Management LLC Sells 671,179 Shares of MacroGenics, Inc. (NASDAQ:MGNX)

May 27, 2025 | marketbeat.com

MacroGenics (NASDAQ:MGNX) Lowered to "Sell" Rating by Wall Street Zen

May 24, 2025 | marketbeat.com

B. Riley Predicts MacroGenics' Q2 Earnings (NASDAQ:MGNX)

May 24, 2025 | marketbeat.com

Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies

May 23, 2025 | nasdaq.com

MacroGenics, Inc. (NASDAQ:MGNX) Holdings Lifted by Frazier Life Sciences Management L.P.

May 23, 2025 | marketbeat.com

4 Medical Product Stocks to Watch From a Challenging Industry

May 21, 2025 | zacks.com

MacroGenics, Inc. (NASDAQ:MGNX) Shares Sold by Vestal Point Capital LP

May 21, 2025 | marketbeat.com

6MGNX : 4 Analysts Assess Macrogenics: What You Need To Know

May 20, 2025 | benzinga.com

MacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

May 16, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?
By Jeffrey Neal Johnson | May 22, 2025
View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?

CALC, MGNX, IVVD, and GALT Company Descriptions

CalciMedica NASDAQ:CALC

$1.69 0.00 (0.00%)

As of 06/18/2025 04:00 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Galectin Therapeutics NASDAQ:GALT

$3.29 +0.90 (+37.66%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$3.29 0.00 (0.00%)

As of 06/18/2025 07:59 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Invivyd NASDAQ:IVVD

$0.75 +0.02 (+3.05%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$0.74 -0.01 (-1.20%)

As of 06/18/2025 07:49 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

MacroGenics NASDAQ:MGNX

$1.37 0.00 (0.00%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.38 +0.01 (+1.09%)

As of 06/18/2025 07:53 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time